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THE ROLE OF JADE-1 IN DNA MISMATCH DAMAGE AND REPAIR IN 
RENAL CANCER 
RUOYU TIAN 
ABSTRACT 
The von Hippel-Lindau (VHL) tumor suppressor pVHL is lost in 90% of clear-cell 
renal-cell carcinomas (ccRCCs). Jade-1 is a renal tumor suppressor that is normally 
stabilized by pVHL. MutS Homolog2 (MSH2) is a key initiator in DNA mismatch repair 
(MMR). Defects in MMR are associated with genome-wide instability and 
predisposition to certain types of cancer. Mass spectrometry data of immunoprecipitated 
Flag-tagged Jade-1lysates showed signal for MSH2, suggesting Jade-1 may participate in 
MMR. Here, we confirmed an interaction between endogenous MSH2 and endogenous 
Jade-1 by coimmunoprecipitation. Using cell fractionation, we found that MSH2 and 
Jade-1 translocated to the nucleus in response to alkylating agent MNNG in kidney 
proximal tubule cells. We also visualized the translocation of Jade-1 by 
immunofluorescence. Silencing JADE1 also influenced the kinetics of MSH2 
translocation. In addition, by colony forming assay, JADE1-silenced cells were resistant 
to mismatch damage induced by MNNG, which is a feature of cells with an MMR defect. 
Furthermore, reintroducing pVHL into renal cancer cells also changed the amount of 
translocated MSH2 and Jade-1. In contrast to wild-type mice, Jade1 heterozygous mice 
got spontaneous tumors, and those tumors continued to show heterozygosity for Jade1. 
Taken together, our results identify a mechanism for Jade-1 regulation of MMR through 
its nuclear translocation. pVHL may also contribute to MSH2 and Jade-1 translocation 
 vi 
 
by increasing Jade-1 abundance. These findings establish an early role for Jade-1 in 
MMR, provide further indication that Jade-1 helps maintain genomic stability in the 
kidney and support that Jade-1 is a haploinsufficient renal tumor suppressor. 
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INTRODUCTION 
1.1 Renal-cell carcinoma 
1.1.1 Renal-cell carcinoma 
Renal-cell carcinoma (RCC), is one of the top ten most common cancers in both 
men and women. According to American Cancer Society data, about 61,560 new cases 
of renal cancer were predicted to occur in 2015, 38,270 in men and 23,290 in women, 
and about 14,080 people, 9,070 men and 5,010 women, would die from the disease. 
Symptoms of renal cancer may include hematuria, flank pain and an abdominal mass. 
Initial treatment is often partial or complete removal of the affected kidney. RCC is 
resistant to chemotherapy and radiotherapy. Targeted therapies and immunotherapy have 
become common medical treatments for patients, for example, mTOR inhibitor 
temsirolimus, angiogenesis and tyrosine kinase inhibitors sunitinib and sorafenib and 
PD-1 inhibitor nivolumab.  
Following the 1997 Union Internationale Contre le Cancer and American Joint 
Committee on Cancer guidelines, all malignant RCC tumors were subclassified as clear-
cell renal-cell carcinoma (ccRCC), papillary renal-cell carcinoma, chromophobe renal-
cell carcinoma, collecting duct carcinoma and oncocytoma (Kovacs, Akhtar et al. 1997).  
1.1.2 Clear-cell renal -cell carcinoma 
Among those five types of RCC, ccRCC is the most common, comprising 
70~75% of all cases. ccRCC is a renal cortical tumor, which has the following features. 
The cytoplasm of malignant epithelial cells is clear. The tumor has a compact-alveolar or 
acinar growth pattern, and intricate, arborizing vasculatures intersperse the tumor tissue 
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(Figure 1). Historically, ccRCC is typically characterized by epithelial cells with 
transparent cytoplasm and a clearly distinguishable cell membrane, interlaced with a 
highly vascularized stroma (Figure 2). The translucency of the cytoplasm is effected by 
accumulation of droplets of phospholipids, glycogen and neutral lipids, in particular, 
cholesterol ester, which wash out on histologic preparation and leave an empty 
cytoplasm. Pathophysiologically, ccRCC is thought to originate from kidney proximal 
tubules, so proximal tubule cells are likely to be the precursor cells of this common 
malignancy.  
There are several molecular alterations that are observed in ccRCC: frequent 
alterations of the VHL gene and protein pVHL and its interactive partners, mutations of 
genes in the PI(3)K/AKT pathway and the SETD2, PBRM1 and BAP1 genes (Network 
2013). pVHL is involved in cellular oxygen sensing, which will be discussed further. 
The PI(3)K/AKT pathway regulates the cell cycle and cell survival and is found to be 
highly activated in cancer. Histone-lysine N-methyltransferase SETD2 methylates DNA, 
and its mutation leads to global hypomethylation of DNA promoters and vast changes in 
gene expression. 
 
1.2 Function of pVHL and VHL associated diseases 
1.2.1 VHL and pVHL 
The von Hippel-Lindau gene VHL is located in chromosome 3p25.3, with a size 
of 12.7 kb, and it encodes a tumor suppressor protein called pVHL. pVHL contains 213 
amino acids and its molecular weight is roughly 24-30 KDa. pVHL has two domains: a 
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beta domain, a roughly 100-residue N-terminal domain rich in beta sheet, and an alpha 
domain, a smaller alpha-helical domain including the C terminus.  
1.2.2 The Function of pVHL 
pVHL functions as a tumor suppressor in ccRCC by inhibiting hypoxia-inducible 
gene expression. Those genes encode proteins involved in angiogenesis (e.g., vascular 
endothelial growth factor, VEGF), cell growth (e.g., transforming growth factor alpha, 
TGF-α), glucose uptake (e.g., GLUT-1 glucose transporter) and acid-base balance (e.g., 
carbonic anhydrase IX, CA9). In normoxia, pVHL, with elongin proteins C and B, binds 
cul2 protein and serves as the receptor subunit of a ubiquitin ligase complex that 
promotes the ubiquitination and destruction of HIF-α transcription factors (Cohen and 
McGovern 2005). In hypoxia, key proline residues of HIF-α cannot undergo 
hydroxylation. The oxygen-dependent hydroxylation of HIF-α is required for pVHL 
binding, and asparagine hydroxylation can also block the interaction of HIF-α with 
transcription coactivator p300 (Cohen and McGovern 2005). In hypoxia, HIF-α is not 
degraded and translocates into the nucleus to bind to p300 to activate downstream 
hypoxia-inducible gene transcription (shown in Figure 3) (Cohen and McGovern 2005).  
1.2.3 von Hippel-Lindau disease 
von Hippel-Lindau (VHL) disease is a rare, autosomal dominant hereditary 
cancer syndrome associated with hemangioblastomas, ccRCC and pheochromocytoma. 
Other features of VHL disease include kidney cysts, pancreatic cysts, epididymal 
cystadenomas, and endolymphatic sac tumors.  
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The VHL tumor suppressor gene was identified in 1993 (Latif, Tory et al. 1993). 
In this disease (Figure 4), one VHL allele is inherited with a mutation. Associated focal 
lesions, such as RCC, arise from the inactivation or silencing of the remaining wild-type 
VHL allele. With accumulation of mutations in additional genes, a ccRCC is formed. 
Defects in VHL account for 90% of ccRCC cases (Kim and Kaelin 2004), which 
represents a high portion of all cases of RCC.  
 
1.3 Jade-1 
1.3.1 JADE1 gene and proteins 
JADE1, Gene for Apoptosis and Differentiation in Epithelia, is also called jade 
family PHD finger 1. JADE1 is located at chromosome 4q28.2, with a size of 65.6 kb. 
JADE1 encodes multiple isoforms of protein, but the two major ones are Jade-1 and 
Jade-1L. Jade-1 (also called Jade-1S), the short form of Jade-1, contains 509 amino acids, 
and Jade-1L, the long isoform of Jade-1, contains 842 amino acid residues.  
Jade-1 was identified from a human kidney cDNA library using a yeast two-
hybrid screen against human pVHL p30 (Zhou, Wang et al. 2002). Jade-1 contains 509 
amino acid residues and its molecular weight is 64 KDa. Jade-1 is a short-lived protein 
and contains a candidate destabilizing PEST motif (a peptide sequence that is rich in 
proline (P),  glutamic acid (E), serine (S), and threonine (T)). As shown in Figure 5, it 
also contains two plant homeodomains (PHD). The PHD zinc-finger domain is about 50-
80 amino acids in length and is found in proteins involved in chromatin-mediated gene 
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regulation. The known post-translational modifications of Jade-1 are phosphorylation 
and ubiquitination (Zhou, Wang et al. 2002). 
Jade-1 is abundant in kidney tissue and kidney proximal tubule cells (Zhou, 
Wang et al. 2002), which are the precursor cells of ccRCC. Jade-1 is located both in 
cytoplasm and the nucleus diffusely and in speckles. Jade-1 is degraded by the 
proteasome pathway. Strikingly, proteasome inhibitor treatment can increase endogenous 
Jade-1 protein levels up to 10 fold (Zhou, Foy et al. 2005).  
1.3.2 Functions of Jade-1 
Jade-1 has multiple roles in the cell cycle, apoptosis, gene regulation and cell 
signaling. Jade-1 is a short-lived protein and is stabilized by pVHL. Jade-1 partly 
colocalizes with pVHL. The reintroduction of pVHL into renal cancer cells increases 
Jade-1 abundance and increased its half life up to 3 fold (Zhou, Wang et al. 2002).  
Jade-1 acts as a tumor suppressor in renal cancer. It inhibits cell growth by 
inducing apoptosis. Jade-1 decreases the abundance of antiapoptotic Bcl-2 (Zhou, Foy et 
al. 2005). The protein level of Jade-1 is barely detectable in renal cancer cell lines (Zhou, 
Foy et al. 2005). According to our laboratory’s analysis of The Cancer Genome Atlas 
(TCGA) database, JADE1 mRNA levels are low in ccRCC, and low JADE1 is 
significantly associated with advanced tumor stage, high pathologic grade and more 
patient deaths (Zeng, Bai et al. 2013).  
Jade-1 regulates the Wnt signaling pathway by directly binding and 
ubiquitylating the oncoprotein β-catenin. The well-established β-catenin E3 ubiquitin 
ligase component β-TrCP only ubiquitylates phosphorylated β-catenin. Jade-1 
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ubiquitylates both phosphorylated and non-phosphorylated  β-catenin, but exhibits 
preference for the phosphorylated form. Moreover, pVHL downregulates β-catenin in a 
Jade-1-dependent manner and inhibits Wnt signaling. Therefore, the pVHL tumor 
suppressor and Wnt tumorigenesis signaling are directly linked via Jade-1 (Chitalia, Foy 
et al. 2008).  
Activation of PI3K/AKT pathway is another common feature in renal cancer, 
with PTEN loss occurring in 30% of cases. JADE1-silenced renal proximal tubule cells 
show increased AKT activity, transformation and AKT-dependent anchorage-
independent growth. Jade-1 inhibits AKT kinase activity by direct binding of the N-
terminus of Jade-1 to both the catalytic domain and C-terminal regulatory tail of AKT. 
Moreover, reintroducing pVHL in renal cancer cells increased endogenous Jade-1 and 
hence reduced the level of phospho-AKT (Zeng, Bai et al. 2013). These observations 
suggest a new mechanism of superactive action of AKT with PTEN inactivation, pVHL 
loss and decreased Jade-1 levels in RCC. 
Jade-1 is also associated with histone acetyltransferase (HAT) activity. Both 
Jade-1 and Jade-1L positively regulate HBO1 complex HAT activity. Co-expression of 
Jade-1 and HBO1 increase acetylation of endogenous histone H4 in epithelial cells in a 
synergistic manner. Jade-1 functions by direct binding with HBO1 via a Jade-1 PHD 
domain. Deletion of a Jade-1 PHD finger not only completely affected the binding, but 
also abolished the synergistic Jade-1/1L- and HBO1-mediated histone H4 acetylation 
(Foy, Song et al. 2008). 
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In summary, Jade-1 is a novel tumor suppressor in ccRCC. It has multiple roles 
in signal transduction through direct protein-protein interaction with other functional 
targets. For example, Jade-1 binds and is stabilized by pVHL. Jade-1 acts as an E3 ligase 
of β-catenin in the regulation of Wnt pathway. Jade-1 also binds to the catalytic domain 
and regulatory tail of AKT and inhibit its kinase activity. Jade-1 upregulates the HAT 
activity of the HBO1 complex. Jade-1L may have some different roles from Jade-1, such 
as transcription elongation (Saksouk, Avvakumov et al. 2009) and DNA replication 
(Miotto and Struhl 2010). 
 
1.4 DNA Mismatch Repair 
DNA mismatch repair (MMR) is a highly conserved biological pathway that 
plays a key role in maintaining genomic stability. Defects in MMR are associated with 
genome-wide instability and predisposition to certain types of cancer, including Lynch 
syndrome, also known as hereditary non-polyposis colorectal cancer (HNPCC).  
1.4.1 DNA mismatch damage 
DNA damage accumulates in cells over time as a result of both exogenous and 
endogenous stimuli. The exogenous stimuli include chemical and physical agents that the 
cells may be exposed to, for example, polychlorinated biphenyls, dioxin, cigarette smoke 
and UV light. The endogenous reactive metabolites include reactive oxygen and nitrogen 
species (ROS and NOS) (Iyer, Pluciennik et al. 2006). Another source of DNA damage 
are the errors occurring during DNA replication and recombination, including the errors 
  8 
made by DNA polymerases. The specificity of MMR is primarily for base-base 
mismatches and insertion/deletion mispairs.  
Methylnitronitrosoguanidine, or N-Methyl-N′-nitro-N-nitrosoguanidine (MNNG) 
is a carcinogen and mutagen that acts by adding alkyl groups to the O6 of guanine and O4 
of thymine, which can lead to transition mutations between GC and AT, shown in Figure 
6. MNNG has been widely used as a chemical tool to induce mismatch damage in tissue 
culture cells (Andrabi, Umanah et al. 2014) and animal models (O'Connell, Klein-Szanto 
et al. 1986).  
1.4.2 The DNA mismatch repair pathway 
The E. coli MMR system includes the following proteins: MutS, MutL, MutH, 
DNA helicase II (MutU/UvrD), four exonucleases (ExoI, ExoVII, ExoX, and RecJ), 
single stranded DNA binding protein (SSB), DNA polymerase III, and DNA ligase 
(Lamers, Perrakis et al. 2000). MMR is highly conserved between human and E. coli, 
shown in Table 1.  
In mammalian cells, the MutS heterodimeric complexes initiate MMR. MutS 
contains two complexes, MSH2-MSH6 (MutSα) and MSH2-MSH3 (MutSβ). MutSα and 
MutSβ recognizes different mispairs: MutSα recognizes base-base mispairs and single 
base insertion/deletions, while the MutSβ complex is primarily responsible for larger 
insertion/deletions up to 13 nucleotides long (Kolodner and Marsischky 1999). The 
MutS complexes undergo ATP-hydrolysis-dependent conformational change, and the 
ADP-bound form disassociates from the recognized mispair following the recruitment of 
a MutL complex and binding to the MSH2-containing complex. The interaction between 
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MutS and MutL requires ATP, although it is not clear that the ATP-binding site of MutL 
or MutS or both are involved (Kolodner and Marsischky 1999). MutL (MLH1-PMS2 
heterodimer) is an endonuclease, which incise of mismatched DNA and is an important 
component in MMR (Li 2008). The endonuclease activity of MutL requires the presence 
of the mismatch recognition factor MutS, a DNA mismatch, a pre-existing strand break, 
the PCNA clamp, the RFC clamp loader and ATP (Li 2008). Incisions produced by 
MutL serve as entry sites for MutS-activated exonuclease I to excise the mismatch DNA 
in a 5’-3’ direction (Li 2008). The generated gap is removed by the DNA polymerase 
delta holoenzyme (Li 2008).   
The later steps in MMR are called the formation of incision, postincision and 
DNA resynthesis/ligation complexes, shown in Figure 8. Many other protein components 
that participate in various DNA processing pathways are also involved in MMR. The 
participating proteins and their functions are shown in Table 1. 
1.4.3 MSH2 and HNPCC 
MutS Homolog 2 (MSH2), also called HNPCC, is homolog to the bacterial MutS 
gene and is located at chromosome 2p21, with a size of 159.3 kb. It encodes a 943 amino 
acid protein with 104.7 KDa mass. MSH2 contains a DNA binding domain and two 
protein interaction domains, one for MSH3 or MSH6 and the other for MutL homologs, 
shown in Figure 9. It is located both in the cytoplasm and nucleus.  
Lynch syndrome, also called hereditary nonpolyposis colorectal cancer (HNPCC), 
is an autosomal dominant genetic condition. Lynch syndrome increases the risk of many 
types of cancer, particularly colorectal cancer, which are cancers of the colon and rectum. 
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Lynch syndrome patients also have an increased risk of cancers of the endometrium, 
ovaries, stomach, small intestine, liver, gallbladder duct, kidney and upper urinary tract, 
and brain (Vasen, Watson et al. 1999). 
Inherited mutations in the MSH2 gene are found in about 40 percent of all cases 
of Lynch syndrome with an identified gene mutation (Fishel, Lescoe et al. 1994). The 
mutated MSH2 may cause the translation of an unusually short or inactive MSH2 protein 
that cannot function properly. The dysfunction or the absent of MSH2 leads to the 
increasing number of DNA mistakes, which should be repaired during cell proliferation. 
The mistakes accumulate as the cells keep dividing, which may cause the cells to 
function aberrantly, increasing the risk of tumor formation in the colon or other parts of 
the body. 
The association between MSH2 expression and the incidence of ccRCC is not 
clear yet. But there is evidence that MSH2 may be a useful marker for predicting TNM 
stage and prognosis in ccRCC (Yoo, Won et al. 2014). Tumor stage was significantly 
higher in the MSH2-negative patients than in the MSH2-positive patients. It was not 
significantly different in terms of N stage and M stage (Yoo, Won et al. 2014). The 
MSH2-negative group presented decreased rates of survival without recurrence, without 
progression and overall survival, even though it did not achieve statistical significance 
results, as shown in Figure 10 (Yoo, Won et al. 2014).  
 
1.5 Current Study 
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In order to identify proteins that interact with Jade-1, a PhD student, Ms. Delia 
Lopez, in our laboratory immunoprecipitated Flag-Jade-1 and Flag-5’UTR-Jade-1 and 
excised coimmunoprecipitated protein bands appearing at various molecular weight 
regions that are not visible in the control IgG IP. These bands were sent for mass 
spectrometry at the University of Massachusetts Medical School, shown in Figure 11. 
Interestingly, there was an overrepresentation of DNA repair proteins. There are 
approximately 165 proteins involved in the DNA damage response and 14 of these were 
identified, including MSH2, which I have pursued on my own. We hope that this study 
can provide insight into how the DNA mismatch repair pathway is regulated in ccRCC 
and identify novel targets for renal cancer treatment.  
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Figure 1: Clear-cell renal-cell carcinoma.  
Typical gross presentation of a clear-cell renal-cell carcinoma (lower left) with a golden 
color due to intracellular lipid accumulation. White areas are foci of sarcomatoid 
differentiation (http://emedicine.medscape.com/article/1612043-overview).  
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Figure 2: Histologic slide of clear-cell renal-cell carcinoma.  
Typical histologic appearance of clear-cell renal-cell carcinoma on hematoxylin and 
eosin stain, showing nests of epithelial cells with clear cytoplasm and a distinct cell 
membrane, separated by a delicate branching network of vascular tissue 
(http://emedicine.medscape.com/article/1612043-overview).  
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Figure 3: The regulation of HIF-α by pVHL in normoxia and hypoxia.  
In normoxic conditions HIF-α is hydroxylated on two proline residues by a proline 
hydroxylase and on an asparagine residue by an asparagine hydroxylase. 
Hydroxylation of HIF-α permits binding of HIF-α to pVHL, which promotes the 
ubiquitination and destruction of HIF-α by the proteasome pathway. In hypoxic 
conditions, HIF-α is not hydroxylated and so it cannot bind pVHL and is stabilized. HIF-
α and HIF-β form a heterodimer, binding with p300 in the absence of oxygen to activate 
downstream hypoxia-inducible gene expression (Cohen and McGovern 2005). 
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Figure 4: The development of clear-cell renal-cell carcinoma. 
In contrast to sporadic renal-cell carcinoma (A), fewer steps are required for the 
development of renal-cell carcinoma in the inherited forms of the disease (B). As a result, 
the renal cancers associated with VHL disease occur earlier and are often multifocal. A 
plus sign represents the wild-type allele, a minus sign represents a null allele (Cohen and 
McGovern 2005).  
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Figure 5: Protein structure of Jade-1. 
Jade-1 contains a candidate PEST domain and two zinc-binding PHD domains (Zhou, 
Wang et al. 2002). 
 
 
 
 
 
Figure 6: The alkylation of guanine. 
The alkylation product of the O6 of guanine prefers thymine, instead of cytosine, with 
which to form hydrogen bonds during DNA replication. With DNA replication, guanine 
alkylation can cause GC to AT transitions.  
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Figure 7: The damage targets of MutS and MutL complexes.  
MSH2-MSH6 recognizes base-base mispair, while MSH2-MSH3 detects 
insertion/deletion mispairs up to 13 nucleotides long (Kolodner and Marsischky 1999). 
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Figure 8: DNA mismatch repair pathway in E.coli. 
MutS starts the initiation process: while MutSα preferentially recognizes base-base 
mismatch, MutSβ recognizes larger mispairs. MutLα possesses an ATPase activity and 
uses ATP to bind with MutS and form a preincision complex. MutH, a very weak 
endonuclease, is activated once bound to MutL. MutH nicks unmethylated DNA and the 
unmethylated strand of hemimethylated DNA. By adding MutH into the complex, the 
incision complex is formed. UvrD is a DNA helicase and facilitates the process. Single-
strand DNA-binding protein (SSB) and exonucleases are added to the complex to excise 
the mispairs, following by DNA resynthesis 
(http://www.mm2m.eu/general/perspectives.html.). 
 
 
 
 
 
Figure 9: Diagram of the MSH2 in scale. 
Numbers inside the grey boxes indicate the exon from which each part of the protein is 
translated. The boxes inside represent the DNA binding domain (red), the 
hMSH3/hMSH6 interaction domain (yellow) and the MutL homologs interaction domain 
(green); C: Carboxy terminus; N: Amino terminus 
(http://atlasgeneticsoncology.org/Genes/GC_MSH2.html). 
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Figure 10: The association of MSH2 negative status versus the positive group with 
recurrence-free survival (A), progression-free survival (B) and overall survival (C) 
in 129 ccRCC patients. 
The 129 ccRCC patients were analyzed according to the degree of MSH2 expression by 
immunohistochemistry. The MSH2-negative group showed trends for decreased rates of 
recurrence-free survival, progression-free survival and overall survival, without 
achieving statistical significance, compared to MSH2-positives (Yoo, Won et al. 2014). 
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Figure 11: Silver staining of coimmunoprecipitated proteins with Flag-Jade-1 and 
Flag-5’UTR-Jade-1 immunoprecipitations.  
Intense bands marked with blue arrows are not visible in the control IgG IP, and they 
were cut out and sent for mass spectrometry, yielding samples at around 125, 100, 85, 70 
and 37 KDa. The black and red markers show the molecular weight of protein markers 
(from Ms. Delia Lopez, PhD student in Dr. Cohen’s laboratory). 
 
 
 
 
 
  22 
 
Table 1. MMR components and their functions. 
a, Major components in cells; b, Not yet identified. (Iyer, Pluciennik et al. 2006) 
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METHODS 
 
2.1 Materials  
2.1.1 Cell lines 
HEK293T and HK-2 cells were grown in Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 4.5g/L glucose and L-glutamine, 10% fetal bovine serum, 
and penicillin-streptomycin. Renal cancer 786-O cells were grown in RPMI 1640 
supplemented with L-glutamine, 10% fetal bovine serum, and penicillin-streptomycin.  
HK-2 nonsi, JADE1 sh1 and JADE1 sh2 stable cell lines were maintained with 2 
µg/ml puromycin. The 786-O Flag-VHL and Flag-ctrl renal cancer cell lines were 
maintained with 0.2 µg/ml G418. All cell lines were grown at 37°C in 5% CO2.  
2.1.2 Antibodies 
Jade-1 rabbit polyclonal antiserum was produced previously as described [3]. MSH2 
mouse and rabbit monoclonal antibodies and fibrillarin, β-actin and α-tubublin mouse 
monoclonal antibodies were from Cell Signaling Technology. pVHL antibody was from 
BD Pharmingen. Normal rabbit and mouse IgG were from Santa Cruz Biotechnology. 
Horseradish peroxidase-linked anti-rabbit and anti-mouse IgG secondary antibodies for 
immunoblotting were from Bio-Rad. Oregon Green 488 goat anti-rabbit IgG secondary 
antibody was from Molecular Probes. Alexa Fluor 594 donkey anti-mouse IgG 
secondary antibody was from Invitrogen. 
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2.1.3 Chemicals 
Dimethyl sulfoxide (DMSO) and O6-Benzylguanine were from Sigma. MNNG was 
from TCI America. 
 
2.2 Methods 
2.2.1 Extraction of whole cell lysates 
Media was removed, and residual media was removed and cells were washed with 
1X PBS. Proper volume of cold whole cell lysis buffer (1X TBS, 3 mM EDTA, 1% 
Triton X-100, 1mM PMSF and proteasome inhibitor tablet) was added onto the plate to 
lyse cells. The volume depended on the cell confluency and cell type. Cells were 
incubated with lysis buffer on ice for 5 minutes, then were scraped into a 1.5 ml 
eppendorf tube. Cells were lysed on ice for 10 minutes. Meanwhile, the tube was 
vortexed every 3 minutes. The extract was centrifuged for 15 minutes at 14,000 rpm in a 
cold centrifuge. The supernatant was collected into a new cold eppendorf tube for further 
use. The protein lysates were stored at -80°C.  
2.2.2 Cytoplasmic and nuclear fractions 
Cold cytoplasmic, nuclear lysis buffer and wash buffer were made with following 
ingredients: 
1) Cytoplasmic lysis buffer: 20 mM HEPES pH 7.4, 10 mM KCl, 2 mM MgCl2, 0.5% 
NP-40, protease inhibitor tablet and 1 mM PMSF. 
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2) Nuclear lysis buffer: 20 mM HEPES pH 7.4, 10 mM KCl, 2 mM MgCl2, 0.5% NP-40, 
0.5 M NaCl, protease inhibitor tablet and 1 mM PMSF. 
3) Wash buffer: 20 mM HEPES pH 7.4, 10 mM KCl, 2 mM MgCl2, protease inhibitor 
tablet and 1 mM PMSF. 
 Media was suctioned out of each plate, and residual media was removed. And cells 
were washed with 1X PBS. The 0.2 ml cytoplasmic lysis buffer was added onto each 10 
cm plate to lyse cells. Cells were scraped into a 1.5 ml eppendorf tube and were 
resuspended to mix thoroughly. Cells were lysed for 10 minutes on ice and were spun 
down at 2000 rpm for 3 minutes in a cold centrifuge. The supernatant was collected in a 
new pre-chilled tube to get the pre-cytoplasmic fraction. The nuclear pellet was washed 
with 500 ml wash buffer three times. The tube was tapped and inverted a couple of times 
and was spun down at 4000 rpm for 5 minutes. The 40-60 µl nuclear lysis buffer was 
added to resuspend and lyse the nuclear pellet for 10 minutes on ice. The pellet was 
vortexed at a low speed every 2 minutes to lyse the pellet completely. The nuclear pellet 
and pre-cytoplasmic fraction were spun down at 14000 rpm for 20 minutes in cold room. 
The supernants were collected into new cold eppendorf tubes for further use. The protein 
lysates were stored at -80 °C.  
2.2.3 Bradford protein assay and sample preparation 
1 ml Bradford (Bio-rad) was added into 2 µl protein lysate and was mixed with 
protein lysate. 900 µl of the sample was added into spectrometer to measure the 
absorption at 595 nm. The standard curve was used to calculate the protein concentration.  
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6X protein sample buffer was added into protein lysate to denature the protein at 95 
°C for 5 minutes. Then the samples were stored at -20 °C if those were used within 10 
days. For longer storage, protein samples were stored at -80 °C.  
2.2.4 Immunoblot 
Protein samples were melted on ice from fridge. Samples were mixed with pipette 
and were span down at 3000 rpm for 1 minute. SDS-PAGE gels were prepared as 
following: 10 ml 7.5% separating gel: 5 ml dH2O, 2.5 ml 1.5 M Tris pH 8.8, 2.5 ml 30% 
Acrylamide/Bis, 50 µl 10% APS, 10 µl TEMED; 5 ml 4% stacking gel: 3.1 ml dH2O, 
1.25 ml 1.5 M Tris pH 6.8, 0.65 ml 30% Acrylamide/Bis, 25 µl 10% APS, 5 µl TEMED. 
The protein samples were loaded into wells of the gel. The maximum volume for each 
well was 60 µl. The gels were run at 20 mA per gel for about 2 hours. The protein was 
transfered from the gels to nitrocellulose membrane at 100V for 1 hour in the cold room. 
Transfer buffer can be used twice. The nitrocellulose membranes were blocked with 5% 
non-fat milk in PBST (1X PBS, 0.1% Tween 20) for 45 minutes to 1 hour at room 
temperature. The membranes were incubated with primary antibodies (diluted with 1% 
milk in PBST) in the cold room overnight. Jade-1 antiserum was diluted 1: 250. The 
primary antibodies were stored at -20 °C and were used multiple times. The membranes 
were washed with PBST for 10 minutes, 3 times, with shaking. Then, they were 
incubated with secondary antibodies (1: 5000 dilute in 1% milk in PBST) at room 
temperature for 1 hour or at 4 °C overnight. The membranes were washed again with 
PBST for 10 minutes, 3 times, with shaking. The protein signals from the membranes 
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were detected by enhanced chemiluminescence (ECL) and autoradiography. Finally, 
films were scanned and the signals were quantified by Image J software. 
2.2.5 Immunoprecipitation (IP) 
Whole cell lysates were prepared as in 2.2.1 by using IP lysis buffer (1X TBS, 3mM 
EDTA, 1% NP-40). The 1.25 mg protein with 0.5 ml whole cell lysis buffer was used as 
one IP group in a 1.5 ml eppendorf tube. The proteins were pre-cleared with washed 20 
µl protein A/G beads at 4 °C for 1 hour. Beads were spun down at 3500 rpm for 5 
minutes in a cold centrifuge. The supernants were pre-cleared protein, that did not non-
specifically bind to agarose beads. The pre-cleared protein lysates were incubated with 
primary antibodies on a 4 °C rotator overnight. The dilution of primary antibodies was 
performed according to their data sheets. Normal rabbit or mouse IgG was used as 
negative control. The next day, IP samples were incubated with 25 µl washed beads in a 
4 °C rotator for 3.5 hours. The antibody, precipitated and co-precipitated protein 
complexes were attached on the beads. The beads were spun down at 3500 rpm for 3 
minutes in a cold centrifuge and then, were washed with 500 µl IP lysis buffer for 3 
times to wash away those weak binding proteins. The beads were washed with 1X PBS 
again. The 40 µl 2X sample buffer was added to resuspend the beads for immunoblotting. 
IP samples were stored at -80 °C or -20 °C for 10 days. 
2.2.6 Immunofluorescence 
Sterilized coverslips were plated into wells of 12-well plates before passaging cells. 
Cells were grown on coverslips 18 h to 24 h before fixation. Cells were treated or 
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transfected if needed. Media was removed and cells were washed with cold PBS. The 
samples were fixed with 400 µl 3.7 % paraformaldehyde (PFA) in PBS, pH 7.4 for 15 
minutes at room temperature. Fixed samples were washed twice with cold PBS. If the 
target protein was an intracellular protein, then samples were permeabilized with 400 µl 
0.25% Triton X-100 in PBS for 10 minutes at room temperature. Samples were washed 
with PBS three times, 5 minutes each. Samples were blocked with 1% BSA in PBST (1X 
PBS, 0.5 % Triton X-100) for 30 minutes at room temperature. Samples were incubated 
with 200 µl diluted primary antibodies with blocking buffer for 1 h at room temperature 
or 4 °C overnight. The dilution factor for primary antibodies was from their data sheets. 
The dilution factor of Jade-1 antiserum was 1:250 and incubation time was 1 h at room 
temperature. Samples were washed with PBS for 4 times, 5 minutes each time, then were 
incubated with 200 µl 1:1000 diluted fluorescein linked secondary antibodies for 1 h at 
room temperature in the dark. Samples were washed again with PBS for 4 times, 5 
minutes each time. The coverslip was mounted with one drop of mounting medium with 
DAPI and sealed with nail polish. The slides were checked in a confocal or fluorescent 
microscope and were stored at 4 °C in the dark.  
2.2.7 Colony forming assay 
Cells were trypsinized and counted, then seeded into 6-well plates. Cells in the 
control groups were less than the treatment groups. After 18 h to 24 h later, cells were 
treated or transfected if necessary. After treatment, cells were washed with fresh media 
and were fed with 2 ml fresh media per well. Cells were grown at 37 °C in 5% CO2 for 
about 2 weeks. Cells were checked under the microscope frequently. Fresh media were 
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added during the 2 weeks if needed. When most of the single cells grew to colonies 
(more than 50 cells), cells were collected and washed with cold PBS. Then, 1 ml 0.5% 
crystal violet was added into each well to stain the cells for at least 30 minutes. Crystal 
violet was removed, and the plates were washed with tap water 3 times. Plates were dried 
on the bench, and colonies were counted manually with the aid of a marker pen.  
2.2.8 DNA isolation 
Mouse tissue samples were incubated with 200 µl 50mM NaOH at 95 °C for 30 
minutes, then were vortexed to destroy the tissue structure. Then, 50 µl 1M Tris (pH 8.0) 
to NaOH was added into each sample. Samples were span down at 12000 rpm for 6 
minutes. The supernant contained the genomic DNA. DNA samples were stored at -80 
°C or 4 °C for short.  
2.2.9 Genotyping (PCR) 
Forward primer: 5’-GATGTTAAGAGTGGCATCCTGG-3’ 
Reverse primer for wild-type band: 5’-ACATCTAGGAGTGGAACACTAG-3’ 
Reverse primer for mutant band: 5’-CCACCACGGGTTCTTCTGTTAG-3’ 
PCR reagents were added and mixed in eppendorf tubes as follows: 5 µl ddH2O, 10 
µl 2X PCR mixture, 2 µl 10 pmol/µl forward primer, 2 µl 10 pmol/µl reverse primer, 1 
µl DNA.  
PCR cycles were run as follows:  
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94 °C, 2 min;  
                            94 °C, 1 min; 
         30 cycles           54 °C, 45 s; 
                            72 °C, 1 min; 
                            72 °C, 1 min; 
                            4 °C, forever. 
The PCR products were loaded into 1% agarose gel. The gel was run at 100V for 30 
minutes. The mutant bands appeared at 800 bp and the wild-type ones were at 620 bp.  
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RESULTS 
3.1 Endogenous Jade-1 protein binds endogenous MSH2 protein 
When human embryonic kidney cells HEK 293T cells were grown to 50% - 60% 
confluence, Flag-JADE1 expression vector was transfected. After 2 days expression, cell 
lystes were collected and immunoprecipitated with Flag antibody linked beads or MSH2 
antibody. Immunoprecipitated samples were immunoblotted with MSH2 or Flag 
antibody, respectively. Figure 12 shows that in the Flag IP sample, MSH2 was co-
immunoprecipitated, however, in MSH2 IP sample, Flag-tagged Jade-1 was not co-
immunoprecipitated. It suggests that MSH2 and Jade-1 may interact together. 
Further, we used the same technique to examine the interaction between endogenous 
Jade-1 and endogenous MSH2. Human kidney-2 (HK-2) proximal tubule cells, which 
represent a model of clear-cell renal-cell carcinoma (ccRCC) precursor cells, and human 
embryonic kidney cells HEK 293T cells were grown to 80% confluence, and cell lysates 
were collected and immunoprecipitated with Jade-1 polyclonal antiserum or MSH2 
monoclonal antibody. Immunoprecipitated lysates were then immunoblotted with MSH2 
or Jade-1 antibody, respectively. The whole cell lysates were also immunoprecipitated 
with normal rabbit IgG as negative control, and the coimmunoprecipitated samples were 
immunoblotted with Jade-1 and MSH2 antibodies.  
Figure 13 shows that an interaction between endogenous Jade-1 and endogenous 
MSH2 proteins was detected in both directions in HK-2 cells as well as 293T cells. 
Moreover, the intensity of coimmunoprecipitated MSH2 and Jade-1 was stronger in HK-
2 cells, the ccRCC precursor cells, than 293T cells.  
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These experiments further provide evidence and exclude the possibility that MSH2 
interacts with Flag tag in the previous transfection experiment. They also verify the mass 
spectrometry data, shown in Figure 11, and also suggest that Jade-1 may participate in 
DNA mismatch repair through interaction with MSH2, one of its key initiators.  
 
3.2 Jade-1 translocates to the nucleus following DNA mismatch damage 
3.2.1 Jade-1 does not regulate the abundance of MSH2  
In order to test the hypothesis that Jade-1 regulates MSH2 protein abundance by 
protein binding, we silenced JADE1 in HK-2 cells to check for changes in MSH2 protein 
level by immunoblot. As shown in Figure 14, with the Jade-1 protein abundance 
knocked down, the MSH2 protein level is unchanged. There is also no difference 
between the JADE1 (JADE1 sh2) alone knock down or JADE1 and JADE1L knock down 
(JADE1 sh1). Therefore, Jade-1 does not alter the abundance of MSH2 protein. There 
may be other mechanisms by which Jade-1 regulates MSH2 and participates in MMR. 
3.2.2 Jade-1 and MSH2 translocate into the nucleus with MNNG treatment 
Alkylguanine-alkyltransferase (AGT) repairs DNA by transferring the alkyl group 
from the O-6 position of guanine to a cysteine. O6-Benzylguanine (O6-BG) is an 
inhibitor of AGT that acts as false substrate for AGT (Berg, Murry et al. 1998). O6-BG 
increases the cell sensitivity to agents that alkylate the O-6 position of guanine, such as 
MNNG. Therefore, we used O6-BG to pretreat cells to inhibit AGT activity and then 
induced mismatch damage with alkylating agent MNNG. 
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As shown in immunoblots in Figure 16A, Jade-1 and MSH2 abundance in the 
nucleus increased in HK-2 cells in response to MNNG. The accumulation of MSH2 and 
Jade-1 started at 0.5 h. MSH2 and Jade-1 continued increasing until 4 h and Jade-1 
increased 12.5 fold. Plus, the Jade-1 and MSH2 showed similar timing of movement, 
gradually increasing to the 4 h time point. Moreover, we have done immuocytochemistry 
to visualize the translocation of Jade-1 with MNNG treatment. We chose a 1 h time point 
for treatment since the immunoblot result shows Jade-1 accumulated in the nucleus at 1 h. 
As shown in Figure 16B, the difference of fluorescence intensity of nucleus and 
cytoplasm in control group is less significant as the one in treatment group. It shows that 
the movement of Jade-1 and MSH2 from cytoplasm to nucleus exists. Moreover, there 
were more nuclear speckles with MNNG treatment than control. Those speckles likely 
represent some functional regions in nucleus where Jade-1 may localize, but the specific 
function of proteins which gather in these speckles is not clear yet. Taken together, 
MSH2 and Jade-1 may bind and move together into the nucleus when cells are damaged.  
It has been reported already that in response to alkylating agents, MSH2 translocates 
from the cytoplasm to nucleus (Christmann and Kaina 2000). Our experiments provide 
new insight into Jade-1 in nuclear translocation in response to DNA mismatch damage.  
 
3.3 JADE1 silencing may change the timing of MSH2 nuclear translocation 
As mentioned in the introduction, our laboratory has focused primarily on the 
physiological and pathological functions of Jade-1 short form, with a molecular weight 
of 64 KDa. The biological roles of Jade-1 and Jade-1L may differ. So, it should be 
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interesting to see the roles of both Jade-1 and Jade-1L in DNA mismatch repair. We have 
established JADE1-silenced HK-2 cell lines HK-2 sh1 and HK2 sh2 (Zeng, Bai et al. 
2013). When JADE1 and JADE1L were both knocked down, as shown in Figure 17A, 
MSH2 started translocating at 0.5 h and accumulated to the highest level at 4 h. 
However, in HK-2 nonsi cells (Figure 17B), MSH2 increased rapidly in the nucleus to 
2.4 fold at 0.5 h and reached a peak at 1 h. So we propose that changes in Jade-1 levels 
alter the kinetics of MSH2 translocation with treatment.  
To further test the hypothesis, the HK-2 JADE1 sh2 cell line, which knocks down 
Jade-1 p64 alone, was used to perform the same experiment. The same experiments were 
repeated twice (Figure 17B, a, b), however, the results were different. The average 
amount of MSH2 translocation is presented in Figure 17C. Similar as HK-2 nonsi cells, 
2.5 fold more MSH2 started translocating at the early time point, 0.5 h, and the 
translocation amount reached peak at 1 h and the amount dropped slightly at 4 h. We 
need more experiments to verify this conclusion. JADE1 alone knockdown cells show 
kinetics similar to nonsi cells.  
In conclusion, these experiments suggest that knockdown of both Jade-1 p64 and 
Jade-1L is required to influence the kinetics of MSH2 translocation with MNNG 
treatment.  
 
3.4 pVHL may change the amount of MSH2 and Jade-1 nuclear translocation 
pVHL is a renal tumor suppressor that also regulates Jade-1 protein abundance. The 
expression of endogenous pVHL is absent in most ccRCC cell lines, such as the 786-O 
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cell line. Overexpression of pVHL increases the amount of endogenous Jade-1 by 
stabilizing it (Zhou, Wang et al. 2002). We wished to examine whether pVHL plays a 
regulatory role in DNA mismatch damage through Jade-1.  
We examined the effect of pVHL on MSH2 nuclear translocation in 786-O stable 
cell lines. Pooled 786-O stable cell lines were established that either overexpress Flag-
tagged pVHL or Flag-tagged empty vector. The same experiments have been repeated 
twice in Figure 18 A and B, however the results were not conclusive. It is hard to draw a 
conclusion whether the introduction of pVHL changes the kinetics of Jade-1 or MSH2 
translocation. In Figure 18 C-E, we can see that the fluctuation of both Jade-1 and MSH2 
are stronger in empty vector cells than in pVHL overexpressed cells. In renal cancer cells, 
pVHL may play an inhibitive role in Jade-1 and MSH2 translocation in MMR. Moreover, 
as shown in Figure 18A, pVHL existed exclusively in the cytoplasm and did not move 
into the nucleus. So pVHL is not involved in MMR by nuclear translocation. It is may be 
an upstream regulator of MMR initiation by regulating the abundance of Jade-1. This 
new finding may provide insights into the potential role of Jade-1 in MMR in renal 
cancer, but more experiments are needed. 
 
3.5 JADE1 knockdown cells are resistant to MNNG 
The colony forming assay was first described in 1956 by Puck and Marcus (Puck 
and Marcus 1956). It is a method to determine cell viability to produce a full colony after 
drug treatment. The cell survival is based on the ability of a single cell to grow to a 
colony. A colony is defined as containing at least 50 cells. On a plate, any colony larger 
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or similar in size to the tip of a marker pen is regarded as containing at least 50 cells. It 
usually takes two to three weeks for the cells to form a colony. Colonies are assessed 
after fixing and staining with crystal violet, as shown in Figure 19. 
More colonies were formed in JADE1-silenced cell lines with or without treatment 
in Table 2A. This observation supports the generalization that Jade-1 inhibits cell growth 
(Zhou, Foy et al. 2005). Colony forming efficiency (CFE) is defined as the percentage of 
seeded cells that go on to form a colony. While CFE reflects a cell’s ability to recover 
and grow after treatment, the ratio of nonsi CFE and silenced cells CFE shows this 
relative ability with silencing of JADE1, shown in Table 2B. These ratios vary with each 
cell line and treatment group, but they are all greater than 1, which reflects a higher 
survival and growth rate of all JADE1-silenced cells.  
With the treatment of alkylating agent, MNNG, cells with lower expression of Jade-
1 shows higher survival rate (Figure 20). The survival and growth ability of all JADE1-
silenced cells increased 3.5 fold with MNNG treatment, compared to DMSO control 
(Figure 20, JADE1 sh). The survival and growth ability of cells with low expression of 
the short form of Jade-1 increased 6.9 fold, while those with low long and short form of 
Jade-1 increased 1.9 fold. Intriguingly, MSH2-deficient cells also show resistance to 
MNNG (de Wind, Dekker et al. 1995). In the presence of MSH2, when thymidine 
incorporates to methylated guanine, it triggers excision and resynthesis, and results in the 
presence of single-stranded regions. The single-stranded region will lead to double-
stranded gaps when DNA replicates in S phase. This “double-stranded break” is a signal 
for cell death. On the other hand, loss of MSH2 will prevent this process, thus conferring 
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tolerance to methylating agents. So it is possible that Jade-1 short form may contribute to 
normal MSH2 function in the DNA mismatch repair pathway. Cells with low expression 
of Jade-1 and Jade-1L may bypass the methylation in tolerance, as occurs with loss of 
MSH2 (de Wind, Dekker et al. 1995). Alternatively, it is possible that Jade-1 is required 
for the proper initiation of MMR.  
 
3.6 Heterozygosity for Jade1 is found in most of mouse tumors 
In a gene trap screen for genes expressed in the primitive streak and tail bud similar 
to brachyvry during mouse embryogenesis, Jade1 was isolated. Jade1 E148 mice were 
generated by gene trap: β-galactosidase (β-Gal) was inserted into Jade1 to generate a 
null or hypomorphic allele of Jade-1 (Tzouanacou, Tweedie et al. 2003).  
Five of ten Jade1 heterozygous mice had metastatic tumors, while none of wild-type 
ones got tumors. This suggests that Jade-1 is a tumor suppressor. We resected some of 
those tumors, abnormal tissues and some normal tissues, then isolated genomic DNA. 
We performed PCR and X-gal staining for genotyping. Three out of four tumors 
maintained heterozygous for Jade1 (Figure 21). Only the liver tumor did not show a 
mutant band signal. We suspect that probably this is because the total amount of genome 
DNA is not enough to amplify the mutant band since the density of wild type band is 
lower than the others.  
The Knudson hypothesis, also called the two-hit hypothesis, supposes that one 
mutation occurs in each allele of a tumor suppressor gene, two mutations total, are 
required to cause a tumor (Knudson 1971). However, this hypothesis has been modified 
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recently. Some candidate tumor suppressors, particularly haploinsufficient ones, require 
inactivation of only one allele, which supports the motion that heterozygosity for tumor 
suppressor genes can cause cancer (Paige 2003). JADE1 appears to be a haploinsufficient 
tumor suppressor: deletion of one allele of JADE1 can lead to tumor formation. These 
results further indicate that Jade-1 is a haploinsufficient tumor suppressor.  
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Figure 12: Flag-tagged Jade-1 protein binds to endogenous MSH2 protein. 
Flag-JADE1 expression vector was transfected into HEK 293T cells. After 48 hours, 
immunoprecipitations were performed with either Flag antibody linked agarose beads or 
normal rabbit IgG as negative control. Coimmunoprecipitated MSH2 was detected by 
immunoblotting with MSH2 rabbit monoclonal antibody. Likewise, MSH2 was 
immunoprecipitated with MSH2 antibody and then the coimmunoprecipitated lysate was 
immunoblotted with Flag antibody. Five percent of whole cell lysate was used to show 
the expression of Flag-tagged Jade-1 and endogenous MSH2 by immunoblot. These 
figures represent one of two experiments with similar results.  
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Figure 13: Endogenous Jade-1 protein binds endogenous MSH2 protein. 
Coimmunoprecipitation of endogenous Jade-1 with endogenous MSH2 in HK-2 cells (A) 
and HEK 293T cells (B). Immunoprecipitations were performed with either Jade-1 rabbit 
polyclonal antiserum or normal rabbit IgG as negative control. Coimmunoprecipitated 
MSH2 was detected by immunoblotting with MSH2 rabbit monoclonal antibody. 
Likewise, MSH2 was immunoprecipitated with MSH2 antibody and then the 
coimmunoprecipitated lysate was immunoblotted with Jade-1 antiserum. Five percent of 
whole cell lysate was used to show the expression of endogenous Jade-1 and endogenous 
MSH2 by immunoblot. These figures each represent one of two experiments with similar 
results.  
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Figure 14: JADE1 silencing does not affect the abundance of endogenous MSH2 
protein. 
Whole cell lysates were prepared from HK-2 parental control, HK-2 stable cell lines 
nonsilencing (nonsi) control, JADE1 sh1, JADE1 sh2, then the protein abundance of  
MSH2 was assessed by immunoblot. β-actin was used as a loading control. These figures 
represent one of two experiments with similar results.  
 
 
A                                                               B 
                  
Figure 15: Chemical structures of O6-Benzylguanine (A) and MNNG (B). 
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Figure 16: Nuclear translocation of Jade-1 in cells treated with MNNG. 
(A) HK-2 parental cells were pretreated with 4 µg/ml O6-BG for an hour (h) to inhibit 
O6-alkylguanine-DNA alkyltransferase activity, then treated with 50 µM MNNG for 0.5, 
1 and 4 h; DMSO served as vehicle control (veh). MNNG treatment induces formation 
of DNA mismatches. After treatment, cells were collected and the nuclear fraction was 
extracted. The nuclear fraction were assessed by immunoblot with Jade-1 antiserum, and 
MSH2, fibrillarin and α-tubulin antibodies. Fibrillarin was used as nuclear fraction 
marker and α-tubulin as cytoplasmic marker. (B) HK-2 parental cells were pretreated 
with O6-BG for 1 h and then treated with MNNG for 1 h. Cells were treated with DMSO 
(veh) for 2 h as negative control. Cells were fixed and permeabilized by Triton X-100, 
and incubated with Jade-1 antiserum and fluorescent secondary antibody. (a), (b) and (c) 
show the cells treated with DMSO control, while (d), (e) and (f) show cells treated with 
MNNG. (a),(d), Jade-1 fluorescence; (b), (e), DAPI; (c), merged image of (a) and (b); (f), 
merged image of (d) and (e). Figure 16A represents one of two experiments with similar 
results. Figure 16B was done once.  
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Figure 17: JADE1 silencing may change the timing of MSH2 nuclear translocation. 
HK-2 JADE1 nonsi, sh1 and sh2 cells were treated with MNNG, and nuclear fractions 
were obtained as in Figure 15A. (A) The nuclear fraction of HK-2 JADE1 sh1cells was 
assessed by immunoblot with MSH2 antibody, Jade-1 antiserum and fibrillarin, α-tubulin 
antibodies. (B) The abundance of MSH2 and fibrillarin was also assessed in HK-2 nonsi 
and JADE1 sh2 cells. HK-2 JADE1 sh2 cells were assessed twice, a and b, with different 
results .(C) Taken (A) and (B) together, the relative abundance of MSH2, which is the 
density shown in (A) and (B) in the nucleus changes is shown with the timing of 
treatment (hours). The average of the density in two experiments of HK-2 JADE1 sh2 
cells is shown in the JADE1 sh2 curve. 
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Figure 18: pVHL may change the timing of Jade-1 and MSH2 translocation. 
786-O Flag-control and 786-O Flag-VHL renal cancer cells were pretreated with 4 µg/ml 
O6-BG for 1 h, then treated with 5 µM MNNG for 0.5, 1 and 4 h; DMSO is vehicle 
control (veh). Experiments were repeated twice, (A) and (B). After treatment, cells were 
collected, and nuclear fractions were extracted and assessed by immunoblot with Jade-1 
antiserum and MSH2, fibrillarin and α-tubulin antibodies, while cytoplasmic fractions 
were probed with pVHL and α-tubulin antibodies. The relative densitometry of Jade-1 
and MSH2 is shown in (B) and graphed in (C)-(E). The relative abundance of 
cytoplasmic MSH2 of (A) and (B) with time of treatment is shown as a curve in (C). The 
relative abundance of MSH2 and Jade-1 in nuclear fractions of (B) changes with time 
points shown in curves (D) and (E), respectively.   
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Figure 19: Colony forming assay with HK-2 stable cell lines.  
Cells were trypsinized and counted, then 100, 200 and 300 cells were seeded in each well 
for DMSO group, while 500, 800 and 1000 cells were seeded in each well for MNNG 
group. After 18-24 hours, cells were treated with DMSO or 50 µM MNNG. After 45 min 
treatment with MNNG, medium was removed and replaced with fresh medium. Cells 
were grown for about two weeks, then stained with 0.5 % crystal violet, and colonies 
were counted manually. 
DMSO treated: (A) HK-2 parental; (B) nonsi; (C) JADE1 sh1; (D) JADE1 sh2. 
MNNG treated: (a) HK-2 parental; (b) nonsi; (c) JADE1 sh1; (d) JADE1 sh2. 
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Table 2: Colony forming efficiency in HK-2 cell lines treated with MNNG. 
A. Number of cells seeded and colonies formed of HK-2 cell lines. In DMSO control 
group, 600 cells in each cell lines were seeded in three wells; while in MNNG grooup, 
2300 cells in total were seeded, and the total number of colonies were counted.  
B. Colony forming efficiency (CFE) of HK-2 JADE1 sh and HK-2 nonsi cells with 
MNNG treatment. In order to compare the role of Jade-1 in colony formation, the CFE of 
HK-2 parental cells and nonsi cells were processed together as nonsilencing, and JADE1 
sh1 and JADE1 sh2 were regarded as JADE1 sh.  
A 
B 
 CFE (%) 
Treatment DMSO MNNG 
nonsilencing (nonsi) 6.3 0.7 
JADE1 sh1 15.2 3.2 
Ratio (JADE1 sh1 / nonsi) 2.4 4.6 
JADE1 sh2 6.7 5.3 
Ratio (JADE1 sh2 / nonsi) 1.1 7.6 
JADE1 sh 21.9 8.5 
 Number of colonies formed  
Treatment Parental Nonsi JADE1 sh1 JADE1 sh2 Cells seeded 
DMSO 9 29 91 40 600 
MNNG 2 16 74 123 2300 
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Ratio (JADE1 sh / nonsi) 3.5 12.1 
*CFE: Colony Forming Efficiency (%)=number of colonies formed / number of cells 
seeded × 100% 
 
 
 
Figure 20: The resistance to MNNG in JADE1-silenced cells.  
The colony forming experiment was shown in Figure 19. The fold shows colony forming 
efficiency of the HK-2 JADE1 sh1, JADE1 sh2 and JADE1 sh ( all JADE1-silenced cell 
lines) cell lines with MNNG treatment compared to DMSO.  
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Figure 21: Jade1 E148 mouse genotyping and absence of loss of wild-type Jade1 in 
spontaneous mouse tumors. 
Genomic DNA was extracted from mouse tissues, and genotyping was performed by 
PCR. Jade1 wild-type gene was detected with a wild-type reverse primer and the Jade1 
knock-out gene was detected with a mutant reverse primer. These two PCR reactions 
share the same forward primer. The arrows point to expected PCR products. Jade1+/+ 
DNA was used for negative control for the mutant band, while Jade1+/- DNA was used 
for positive control for the mutant band. This experiment showed the same results as 
genotyping by another method, X-gal staining. 
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DISCUSSION 
4.1 DNA mismatch repair in renal cancer 
DNA repair is critical for normal cellular function, and its dysfunction is associated 
with the malignant state. Cells incapable of repairing DNA errors insidiously accumulate 
an escalating number of mutations throughout their genome. Those mutations can apply 
to oncogenes, tumor suppressor genes, and other genes related to oncogenesis (Chung 
and Rustgi 1995). Germline mutation in any of 5 MMR genes, MSH2, MSH6, MLH1, 
PMS1 or PMS2 can cause Lynch syndrome (Rhyu 1996). MS2 mutation was found in 
60% of Lynch syndrome families (Fishel, Lescoe et al. 1994). Biallelic loss of any of 
these MMR genes causes genome-wide instability, a mutator phenotype and 
microsatellite instability (MSI) (Paige 2003). MSI is one of the features of the early 
onset of Lynch syndrome.  
The phenotypic features of Lynch syndrome include, early onset colorectal 
carcinomas (CRC) and a variety of other cancers, particularly carcinoma of the 
endometrium, ovary, stomach, small bowel, ureter, and renal pelvis (Lynch, Shaw et al. 
1966). A study of 446 unaffected carriers of an MMR gene mutation (MSH2, n=222) and 
1029 their unaffected relatives showed that mutation carriers had and 11-fold greater risk 
of renal cancer (95% CI, P<0.001) (Win, Young et al. 2012). Moreover, in another study 
with 129 ccRCC patients, the MSH2 negative group showed trends for decreased rates of 
recurrence-free survival, progression-free survival and overall survival, although it did 
not reach statistical significance (Yoo, Won et al. 2014). Based on this evidence, DNA 
mismatch repair defects may contribute to renal cancer, such as ccRCC. More work is 
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needed to confirm this conclusion. 
 
4.2 Jade-1 may be involved in the initiation process of DNA mismatch repair  
4.2.1 Jade-1 binds to MSH2 
The well-known MHS2 binding proteins are MSH3, MSH6 and the MutL complex. 
MSH2 also recognizes and binds to G-T mismatched base pairs (Figure 9). In our study, 
we first identified Jade-1 as a novel MSH2 binding partner. These observations suggest a 
new role for Jade-1 in MMR. 
The protein interaction between endogenous Jade-1 and endogenous MSH2 in HK-2 
cells is stronger than in HEK 293T cells (Figure 13). HEK 293T cells have a defect in 
MMR: these cells lack hMLH1/hPMS2 but express normal levels of MSH2 (Stojic, 
Mojas et al. 2004). The 293T cells were highly resistance to killing by MNNG, but 
MMR signaling was initiated (Stojic, Mojas et al. 2004). We detected nuclear 
translocation of MSH2 and Jade-1 in 293T cells (data not shown) with MNNG treatment. 
These observations support a role for Jade-1 in the initiation of MMR. Due to the lack of 
MMR, 293T cells should have other supplementary repair mechanisms to compensate 
for the deficiency. This may also help explain the reason why the MSH2 and Jade-1 
interaction is weaker in 293T than in MMR proficient cells.  
4.2.2 Jade-1 regulates kinetics of MSH2 nuclear translocation 
In Msh6 deficient yeast cells, Msh2 translocates to the nucleus, but with decreased 
abundance. Moreover, Msh6 localization depended on the Msh2 nuclear localization 
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signal (NLS) (Hayes, Sevi et al. 2009), suggesting a binding and stabilization pattern of 
MSH2 and MSH6 heterodimer to prevent free monomer accumulation (Hayes, Sevi et al. 
2009). Based on our data, in cells with low levels of Jade-1, the kinetics of MSH2 
translocation changed, although the differences in nuclear MSH2 levels is not conclusive 
(Figure 17). Apart from MSH6, Jade-1, another binding partner of MSH2, may also 
contribute to the balance of abundance of MSH2 monomer and MSH2-MSH6 
heterodimer. Moreover, several of my experiments have shown the timing of Jade-1 and 
MSH2 translocation is similar and may predict a positive role of Jade-1 for MSH2 
nuclear translocation. We need further experiments to illustrate whether Jade-1 and 
MSH2 form a heterodimer to translocate or Jade-1 regulates the amount of nuclear 
MSH2.  
4.2.3 Resistance to MNNG in JADE-1 silenced level cells  
Conventional chemotherapy works to slow or stop cancer cell growth and is 
commonly used to treat solid tumors. Most cancer cells are sensitive to DNA damage, so 
alkylating agents are common cancer chemotherapy drugs. Alkylating agents induce 
DNA lesions that cancer cells are unable to repair, causing apoptosis. However, renal 
cancer is highly resistant to chemotherapy, and no agent is considered standard for its 
treatment. Part of the reason for this is that P-glycoprotein 1, also known as multidrug 
resistance protein 1 (MDR1), is constitutively expressed in the proximal tubule of the 
kidney, liver cells, intestine, capillaries of brain, testes and ovaries to pump out 
xenobiotics, such as drugs and toxins (Chen, Chin et al. 1986).  
Kidney proximal tubule cells with lower levels of Jade-1 show higher survival and 
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growth ability following MNNG treatment. Similar to MSH2-silenced cells, JADE-1-
silenced HK-2 cells showed resistance to MNNG, which suggests similar roles for 
MSH2 and Jade-1 in MMR. Jade-1 expression in ccRCC cells is low (Zhou, Wang et al. 
2002), which may disturb the normal function of MMR, and ccRCC cells show 
resistance to alkylating agents. To overcome chemotherapy resistance, elevation of 
endogenous Jade-1 levels may be a possible approach. ccRCC cells treated with 
proteasome inhibitor showed dramatically increased Jade-1 abundance (Latif, Tory et al. 
1993). Our laboratory is trying to identify small molecules to stabilize or induce 
endogenous Jade-1 that may be useful therapeutics in ccRCC.   
 
4.3 Jade-1 might mediate MMR by pVHL 
  The kinetics of MSH2 translocation was altered in HK-2 JADE1-silenced cells. 
Endogenous Jade-1 protein was low or undetectable in VHL-deficient renal cancer cell 
lines (Latif, Tory et al. 1993). Moreover, Jade-1 is stabilized by pVHL: Jade-1 
abundance is 3- ~ 10-fold higher in VHL-stably transfected cell lines (Zhou, Wang et al. 
2002). We hypothesized that reintroduction of pVHL into VHL-deficient ccRCC cell 
lines may induce more Jade-1 and MSH2 translocation, because nuclear Jade-1 and 
MSH2 increased 12.5-fold and 15.4-fold, respectively, in response to MNNG in HK-2 
parental cells, which have wild-type pVHL. However, the experiments we have done 
showed opposite: more Jade-1 and MSH2 translocated in VHL-null 786-O control cells 
(Figure 18). We need to do more repeat experiments to confirm this point.  
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4.4 Jade-1 in colon cancer   
The most commonly mutated gene in colorectal cancer (CRC) is the adenomatous 
polyposis coli (APC) gene, which encodes the tumor suppressor APC. APC and other 
proteins form a complex to degrade oncoprotein β-catenin. With mutated APC, β-catenin 
level remains high and translocates to the nucleus and activates oncogene transcription. 
Another subset of CRC is HNPCC, which arise from mutations in MMR genes, 
including MSH2. MMR deficiency contributes to microsatellite instability.  
Assessment of tumors from 557 cases of CRC showed that microsatellite instability 
was inversely associated with β-catenin overexpression (Wangefjord, Brandstedt et al. 
2013). Moreover, Jade-1 is involved in MMR and regulates the translocation of MSH2. 
Jade-1 is also an E3 ligase for β-catenin and regulates the degradation of β-catenin. It 
might possible that the MMR and wnt pathway crosstalk via Jade-1.  
Interestingly, in Jade1 E148 mice, 5 of 10 Jade1 heterozygous mice have metastatic 
tumors, 3 of which appear to arise from bowel. Reduced levels of Jade-1 increase the 
probability of bowel tumors in the mice. We need immunohistochemistry (IHC) to 
further characterize the MSH2, Jade-1 and β-catenin level in those mice bowel tumors. 
Furthermore, we can analyze the data in the Catalogue of somatic mutations in cancer 
(COSMIC) to check Jade-1 mutations and expression in CRC, which will provide insight 
into the role of Jade-1 beyond renal cancer.  
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